The CADTH pan-Canadian Oncology Drug Review (pCODR) brings consistency and clarity to the assessment of drugs in Canada. pCODR reviews clinical, economic, and patient evidence, and uses this information to make non-binding recommendations to Canada's public drug plans to support their drug funding decisions.
This section of cadth.ca is relevant to drug manufacturers and tumour groups submitting a request to CADTH for a pCODR review. A summary of the pCODR process, complete with the documentation required to make a drug submission, can be found in the Process in Brief section. You can also find quick links to pCODR documentation under Guidelines, Procedures and Templates.
Before submitting a request for a pCODR drug review, manufacturers and tumour groups must register with pCODR. This will provide access to a secure Submit and Contribute page and enable the electronic delivery of documents to CADTH.
Preparing a Submission
Please ensure that you are proceeding according to the requirements of the full pCODR Procedures, pCODR Submission Guidelines, and other supplemental materials, and not solely according to the Process in Brief. Additionally, please do not download and archive any pCODR documentation, as it is subject to change. Always use the up-to-date version of documents posted on cadth.ca.
Drug Review Information
If you are searching for information on a particular pCODR drug review, you can use the new, more powerful cadth.ca search engine. You can also track the progress of reviews through the pCODR Drug Review Update.
Final reports are freely available to anyone to use, download, or print for non-commercial, personal use, or private research and study, provided you do not modify them and appropriate credit is given to CADTH.
Patient groups and other stakeholders wishing to provide input or feedback on reviews can find what they need in the section of cadth.ca created for that purpose. More general information on pCODR is found on the About pCODR page.